Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Head and Neck Cancer

Free Subscription Articles published in J Nucl Med Retrieve available abstracts of 40 articles: HTML format

Single Articles

April 2024
1. GREENSPAN BS, Hofman MS, Buscombe J
   The Accomplishments and Legacy of Saul Hertz, MD.
   J Nucl Med. 2024;65:659-663.
   PubMed     Abstract available
   
   
   March 2024
2. GREENSPAN BS, Hofman MS, Buscombe J
   Commentary on "Radioactive Iodine: A Living History".
   J Nucl Med. 2024;65:495.
   PubMed    
   
   
   February 2024
3. LEUNG KH, Rowe SP, Sadaghiani MS, Leal JP, et al
   Deep Semisupervised Transfer Learning for Fully Automated Whole-Body Tumor Quantification and Prognosis of Cancer on PET/CT.
   J Nucl Med. 2024 Feb 29:jnumed.123.267048. doi: 10.2967/jnumed.123.267048.
   PubMed     Abstract available
   
   
   
4. KOVACS DG, Ladefoged CN, Andersen KF, Brittain JM, et al
   Clinical Evaluation of Deep Learning for Tumor Delineation on (18)F-FDG PET/CT of Head and Neck Cancer.
   J Nucl Med. 2024 Feb 22:jnumed.123.266574. doi: 10.2967/jnumed.123.266574.
   PubMed     Abstract available
   
   
   January 2024
5. GU B, Yang Z, Du X, Xu X, et al
   Imaging of Tumor Stroma Using (68)Ga-FAPI PET/CT to Improve Diagnostic Accuracy of Primary Tumors in Head and Neck Cancer of Unknown Primary: A Comparative Imaging Trial.
   J Nucl Med. 2024 Jan 25:jnumed.123.266556. doi: 10.2967/jnumed.123.266556.
   PubMed     Abstract available
   
   
   
6. ZHAO L, Pang Y, Fang J, Chen J, et al
   Design, Preclinical Evaluation, and Clinical Translation of (68)Ga-FAPI-LM3, a Heterobivalent Molecule for PET Imaging of Nasopharyngeal Carcinoma.
   J Nucl Med. 2024 Jan 4:jnumed.123.266183. doi: 10.2967/jnumed.123.266183.
   PubMed     Abstract available
   
   
   December 2023
7. VENTURA D, Dittmann M, Buther F, Schafers M, et al
   Diagnostic Performance of [(18)F]TFB PET/CT Compared with Therapeutic Activity [(131)I]Iodine SPECT/CT and [(18)F]FDG PET/CT in Recurrent Differentiated Thyroid Carcinoma.
   J Nucl Med. 2023 Dec 21:jnumed.123.266513. doi: 10.2967/jnumed.123.266513.
   PubMed     Abstract available
   
   
   November 2023
8. GUNTHER T, Holzleitner N, Viering O, Beck R, et al
   Preclinical Evaluation of Minigastrin Analogs and Proof-of-Concept [(68)Ga]Ga-DOTA-CCK-66 PET/CT in 2 Patients with Medullary Thyroid Cancer.
   J Nucl Med. 2023 Nov 9:jnumed.123.266537. doi: 10.2967/jnumed.123.266537.
   PubMed     Abstract available
   
   
   
9. VIERING O, Gunther T, Holzleitner N, Dierks A, et al
   CCK(2) Receptor-Targeted PET/CT in Medullary Thyroid Cancer Using [(68)Ga]Ga-DOTA-CCK-66.
   J Nucl Med. 2023 Nov 2:jnumed.123.266380. doi: 10.2967/jnumed.123.266380.
   PubMed    
   
   
   October 2023
10. LASCHINSKY C, Theurer S, Herold T, Rawitzer J, et al
    Molecular Markers Are Associated with Onset of Radioiodine Refractoriness in Patients with Papillary Thyroid Carcinoma.
    J Nucl Med. 2023 Oct 26:jnumed.123.266044. doi: 10.2967/jnumed.123.266044.
    PubMed     Abstract available
    
    
    June 2023
11. ENKE JS, Bundschuh RA, Wienand G, Reitsam NG, et al
    Somatostatin Receptor Antagonists as a Theranostic Option in Iodine-Refractory Thyroid Carcinoma.
    J Nucl Med. 2023 Jun 15:jnumed.123.265639. doi: 10.2967/jnumed.123.265639.
    PubMed    
    
    
    May 2023
12. MALIHA PG, Mendelsohn AH, Czernin J, Howard T, et al
    Obstructive Sialadenitis from Oral Squamous Cell Carcinoma: [(68)Ga]Ga-FAPI-46 PET-Positive and [(18)F]FDG PET-Negative.
    J Nucl Med. 2023 May 25:265498. doi: 10.2967/jnumed.123.265498.
    PubMed    
    
    
    
13. GABRIELS RY, van Heijst LE, Hooghiemstra WTR, van der Waaij AM, et al
    Detection of Early Esophageal Neoplastic Barrett Lesions with Quantified Fluorescence Molecular Endoscopy Using Cetuximab-800CW.
    J Nucl Med. 2023;64:803-808.
    PubMed     Abstract available
    
    
    April 2023
14. TAPROGGE J, Abreu C, Yusuf S, Ainsworth G, et al
    The Role of Pretherapy Quantitative Imaging and Dosimetry in Radioiodine Therapy for Advanced Thyroid Cancer.
    J Nucl Med. 2023 Apr 28:jnumed.122.264913. doi: 10.2967/jnumed.122.264913.
    PubMed     Abstract available
    
    
    March 2023
15. CIVAN C, Kasper S, Berliner C, Fragoso-Costa P, et al
    PSMA-Directed Imaging and Therapy of Salivary Gland Tumors: A Single-Center Retrospective Study.
    J Nucl Med. 2023;64:372-378.
    PubMed     Abstract available
    
    
    January 2023
16. VON GUGGENBERG E, Uprimny C, Klingler M, Warwitz B, et al
    Preliminary clinical experience of cholecystokinin-2 receptor PET/CT imaging using the (68)Ga-labeled minigastrin analog DOTA-MGS5 in patients with medullary thyroid cancer.
    J Nucl Med. 2023 Jan 19:jnumed.122.264977. doi: 10.2967/jnumed.122.264977.
    PubMed     Abstract available
    
    
    December 2022
17. HERRMANN K, Giovanella L, Santos A, Gear J, et al
    Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center.
    J Nucl Med. 2022;63:1836-1843.
    PubMed     Abstract available
    
    
    November 2022
18. LUMISH MA, Maron SB, Paroder V, Chou JF, et al
    Noninvasive assessment of human epidermal growth factor receptor 2 (HER2) in esophagogastric cancer using (89)Zr-trastuzumab PET: a pilot study.
    J Nucl Med. 2022 Nov 23:jnumed.122.264470. doi: 10.2967/jnumed.122.264470.
    PubMed     Abstract available
    
    
    
19. OEVERHAUS M, Koenen J, Bechrakis N, Stohr M, et al
    Radioiodine ablation of thyroid remnants in patients with Graves' orbitopathy.
    J Nucl Med. 2022 Nov 23:jnumed.122.264660. doi: 10.2967/jnumed.122.264660.
    PubMed     Abstract available
    
    
    
20. ZHOU Q, van den Berg NS, Kang W, Pei J, et al
    Factors for Differential Outcome Across Cancers in Clinical Molecule-Targeted Fluorescence Imaging.
    J Nucl Med. 2022;63:1693-1700.
    PubMed     Abstract available
    
    
    October 2022
21. HU X, Zhou T, Ren J, Duan J, et al
    Response prediction using (18)F-FAPI-04 PET/CT in patients with esophageal squamous cell carcinoma treated with concurrent chemoradiotherapy.
    J Nucl Med. 2022 Oct 13. pii: jnumed.122.264638. doi: 10.2967/jnumed.122.264638.
    PubMed     Abstract available
    
    
    September 2022
22. SUBRAMANIAM RM, DeMora L, Yao M, Yom SS, et al
    (18)F FDG PET/CT Prediction of Treatment Outcomes in HPV-positive, Locally Advanced Oropharyngeal Cancer Receiving De-intensified Therapy: Results from NRG-HN002.
    J Nucl Med. 2022 Sep 2. pii: jnumed.122.264424. doi: 10.2967/jnumed.122.264424.
    PubMed     Abstract available
    
    
    August 2022
23. KRISHNAN G, van den Berg NS, Nishio N, Kapoor S, et al
    Fluorescent Molecular Imaging Can Improve Intraoperative Sentinel Margin Detection in Oral Squamous Cell Carcinoma.
    J Nucl Med. 2022;63:1162-1168.
    PubMed     Abstract available
    
    
    June 2022
24. ZHENG KH, Kroon J, Schoormans J, Gurney-Champion O, et al
    (89)Zr-labeled High-Density Lipoprotein Nanoparticle PET imaging reveals tumor uptake in patients with esophageal cancer.
    J Nucl Med. 2022 Jun 23. pii: jnumed.121.263330. doi: 10.2967/jnumed.121.263330.
    PubMed     Abstract available
    
    
    
25. AVRAM AM, Giovanella L, Greenspan B, Lawson SA, et al
    SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version.
    J Nucl Med. 2022;63:15N-35N.
    PubMed    
    
    
    May 2022
26. SUBRAMANIAM RM, Duan F, Romanoff J, Yu JQ, et al
    (18)F FDG PET/CT Staging of Head and Neck Cancer: Inter-observer agreement and accuracy - Results from multicenter ACRIN 6685 Clinical Trial.
    J Nucl Med. 2022 May 12. pii: jnumed.122.263902. doi: 10.2967/jnumed.122.263902.
    PubMed     Abstract available
    
    
    
27. VERHOEFF SR, van de Donk PP, Aarntzen EHJG, Oosting SF, et al
    (89)Zr-DFO-durvalumab PET/CT prior to durvalumab treatment in patients with recurrent or metastatic head and neck cancer.
    J Nucl Med. 2022 May 5. pii: jnumed.121.263470. doi: 10.2967/jnumed.121.263470.
    PubMed     Abstract available
    
    
    February 2022
28. SIGNORE A, Campagna G, Marinaccio J, de Vitis M, et al
    Analysis of short term and stable DNA damage in patients with differentiated thyroid cancer treated with (131)I in hypothyroidism or with rhTSH for remnant ablation.
    J Nucl Med. 2022 Feb 3. pii: jnumed.121.263442. doi: 10.2967/jnumed.121.263442.
    PubMed     Abstract available
    
    
    December 2021
29. CREFF G, Jegoux F, Palard-Novello X, Depeursinge A, et al
    FDG-PET/CT-based prognostic survival model after surgery for head and neck cancer.
    J Nucl Med. 2021 Dec 9. pii: jnumed.121.262891. doi: 10.2967/jnumed.121.262891.
    PubMed     Abstract available
    
    
    
30. RISOER LM, Clausen MM, Ujmajuridze Z, Farhadi M, et al
    Prognostic value of Urokinase-type Plasminogen Activator Receptor (uPAR)-PET/CT in Head and Neck Squamous Cell Carcinomas and Comparison with (18)F-FDG-PET/CT: A single-center prospective study.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.262866. doi: 10.2967/jnumed.121.262866.
    PubMed     Abstract available
    
    
    
31. PROMTEANGTRONG C, Siripongsatian D, Jantarato A, Kunawudhi A, et al
    Head-to-head comparison of (68)Ga-FAPI-46 and (18)F-FDG PET/CT for evaluation of head and neck squamous cell carcinoma: a single-center exploratory study.
    J Nucl Med. 2021 Dec 2. pii: jnumed.121.262831. doi: 10.2967/jnumed.121.262831.
    PubMed     Abstract available
    
    
    September 2021
32. GU B, Xu X, Zhang J, Ou X, et al
    The Added Value of (68)Ga-FAPI-04 PET/CT in Patients with Head and Neck Cancer of Unknown Primary with (18)F-FDG Negative Findings.
    J Nucl Med. 2021 Sep 30. pii: jnumed.121.262790. doi: 10.2967/jnumed.121.262790.
    PubMed     Abstract available
    
    
    
33. VONK J, de Wit JG, Voskuil FJ, Tang YH, et al
    Epidermal growth factor receptor targeted fluorescence molecular imaging for postoperative lymph node assessment in patients with oral cancer.
    J Nucl Med. 2021 Sep 16. pii: jnumed.121.262530. doi: 10.2967/jnumed.121.262530.
    PubMed     Abstract available
    
    
    August 2021
34. AVRAM AM, Zukotynski K, Nadel HR, Giovanella LM, et al
    MANAGEMENT OF DIFFERENTIATED THYROID CANCER: THE STANDARD OF CARE.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262402. doi: 10.2967/jnumed.121.262402.
    PubMed     Abstract available
    
    
    July 2021
35. GIOVANELLA L, Avram A, Clerc J
    Molecular Imaging for Thyrotoxicosis and Thyroid Nodules.
    J Nucl Med. 2021;62.
    PubMed     Abstract available
    
    
    
36. BERNET VJ, Chindris AM
    Update on the Evaluation of Thyroid Nodules.
    J Nucl Med. 2021;62.
    PubMed     Abstract available
    
    
    
37. DE SOUZA FRANCA PD, Guru N, Kostolansky AR, Mauguen A, et al
    PARP1: A Potential Molecular Marker to Identify Cancer During Colposcopy Procedures.
    J Nucl Med. 2021;62:941-948.
    PubMed     Abstract available
    
    
    March 2021
38. HOPE TA, Graces C, Calais J, Ehman E, et al
    Accuracy of (18)F-fluorocholine PET for the detection of parathyroid adenomas: prospective single center study.
    J Nucl Med. 2021 Mar 5. pii: jnumed.120.256735. doi: 10.2967/jnumed.120.256735.
    PubMed     Abstract available
    
    
    January 2021
39. WHITMAN J, Allen IE, Bergsland EK, Suh IA, et al
    Assessment and comparison of fluorocholine PET and sestamibi scans in identifying parathyroid adenomas: a meta-analysis.
    J Nucl Med. 2021 Jan 15. pii: jnumed.120.257303. doi: 10.2967/jnumed.120.257303.
    PubMed     Abstract available
    
    
    May 2020
40. CHENG L, Sa R, Luo Q, Fu H, et al
    Unexplained Hyperthyroglobulinemia in Differentiated Thyroid Cancer Patients Indicates Radioiodine Adjuvant Therapy: A Prospective Multicenter Study.
    J Nucl Med. 2020 May 1. pii: jnumed.120.243642. doi: 10.2967/jnumed.120.243642.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Head and Neck Cancer is free of charge.